Cipla, Pfizer India partner to market 4 brands in India
What's the story
Pharmaceutical giants Pfizer India and Cipla have announced a strategic partnership. Under the deal, Cipla will exclusively market and distribute four key Pfizer brands in India. The agreement covers cough syrups Corex Dx and Corex LS, non-steroidal anti-inflammatory drug Dolonex, proton pump inhibitor Neksium, and oral antibiotic Dalacin C in India.
Manufacturing details
Pfizer to continue manufacturing, supplying medicines
Pfizer will continue to manufacture, source, and supply these medicines to Cipla for the Indian market. The companies haven't disclosed any financial details about the deal with Pfizer India. Achin Gupta, Global COO of Cipla Ltd., said their distribution capabilities will help reach patients who need these medicines the most.
Enhanced access
Cipla's distribution network to enhance access
Gupta further emphasized that this partnership with Pfizer fits into their strategy of strengthening presence across key therapy areas. He added it will improve access to high-quality treatments, in line with Cipla's purpose of "Caring for Life." Meenakshi Nevatia, Country President at Pfizer India, echoed these sentiments and said the collaboration would effectively meet healthcare needs of millions across India.
Strategic collaboration
Partnership combines Pfizer's innovation with Cipla's distribution network
The Cipla-Pfizer partnership is the first of its kind in India, where Pfizer has been operating for over 75 years. Nevatia said the deal combines Pfizer's legacy of innovation and quality with Cipla's extensive distribution network. This strategic collaboration is expected to address healthcare needs of millions across India effectively.
Market response
Cipla's stock performance and future expectations
Following the announcement of this strategic partnership, shares of Cipla Ltd. were trading at ₹1,504.50, a rise of 0.39%. However, it's worth noting that the stock has fallen by nearly 2% in 2025 so far. The deal is expected to strengthen Cipla's position in respiratory and gastrointestinal segments over the next five years.